Abstract
To the Editor: Silverberg and colleagues (March 23 issue)(1) conclude, on the basis of two phase 3 trials, that lebrikizumab therapy was safe and effe......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
